The EGFR mutant allele is heterogeneous, it may only present in a subset of tumor cells and can occur during cancer evolution; thus, the detection of the drug-resistant EGFR T790M mutation as early as possible before the acquired drug-resistance becomes clinically detectable is important, as it enables the physician to change the therapy promptly and give the patient the most effective treatment. Here, EGFR is linked to cancer.